Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 6/20 | 0.55 |
| ▸ | SLC6A13 | Q9NSD5 | 6/20 | 0.55 |
| ▸ | SLC6A12 | P48065 | 5/20 | 0.55 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.55 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.55 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18299954 | 0.98 | SLC6A11 (0.53) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| SCHEMBL19815606 | 0.85 | SLC6A11 (0.55) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| Hydrochloric Acid SCHEMBL28784255 | 0.83 | SLC6A11 (0.53) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| SCHEMBL13483847 | 0.83 | SLC6A1 (0.40) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| SCHEMBL13483848 | 0.80 | SLC6A1 (0.38) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| SCHEMBL13483849 | 0.80 | SLC6A1 (0.38) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| SCHEMBL18307342 | 0.80 | SLC6A1 (0.38) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| SCHEMBL11050032 | 0.79 | SLC6A11 (0.53) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| Hydrochloric Acid SCHEMBL18299415 | 0.79 | SLC6A1 (0.37) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| SCHEMBL1249676 | 0.78 | SLC6A11 (0.57) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| CN-107820494-B | Nuclear receptor modulators | 艾伯维公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2019-02-21 | — | — | US | disclosed |
| WO-2018021977-A1 | GLYCINE METABOLISM MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | WO | disclosed |
| WO-2016200851-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2016198908-A1 | ROR NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| EP-0751937-A1 | N-(BENZHYDRYLOXYALKYL)-4-(CARBOXY/CARBAMOYL-METHYL)-PIPERIDINE DERIVATIVES AS ANTIDEPRESSANTS | COOPERATION PHARMACEUTIQUE FRANCAISE (FR) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995026336-A1 | N-(BENZHYDRYLOXYALKYL)-4-(CARBOXY/CARBAMOYL-METHYL)-PIPERIDINE DERIVATIVES AS ANTIDEPRESSANTS | COOPERATION PHARMACEUTIQUE FRANCAISE (FR) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | SLC6A11 2278/4885SLC6A13 3458/4885SLC6A12 4492/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | SLC6A11 2278/4885SLC6A13 3458/4885SLC6A12 4492/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | SLC6A11 2278/4885SLC6A13 3458/4885SLC6A12 4492/4885 |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | SLC6A11 2278/4885SLC6A13 3458/4885SLC6A12 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.